Gregory Zante - Viking Therapeutics Vice President - Finance and Operations
| VKTX Stock | USD 51.99 0.60 1.14% |
President
Mr. Gregory S. Zante, CPA serves as Vice President Finance and Operations of the Company. Mr. Zante joins Viking with more than 20 years of accounting and financial experience at public and private companies in the biotechnology and accounting industries. In his new role, he will be responsible for forecasting, scenario analyses, financing strategies, business development support and operational activities. Prior to Viking, Mr. Zante was Chief Financial Officer at Dance Biopharm, a diabetesfocused biopharmaceutical company, where he managed the company private financing strategy and positioned it for initial public offering activities. Mr. Zante has also previously held senior positions at several biopharmaceutical companies including Sangamo BioSciences, Calyx Therapeutics and Matrix Pharmaceuticals. He is a certified public accountant in the state of California and has previously served as a senior staff accountant at Ernst Young. since 2017.
| Age | 53 |
| Tenure | 7 years |
| Address | 9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121 |
| Phone | 858 704 4660 |
| Web | https://www.vikingtherapeutics.com |
Viking Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1268) % which means that it has lost $0.1268 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.155) %, meaning that it created substantial loss on money invested by shareholders. Viking Therapeutics' management efficiency ratios could be used to measure how well Viking Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.24 in 2024. Return On Capital Employed is likely to drop to -0.3 in 2024. At this time, Viking Therapeutics' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 385.6 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 755.8 K in 2024.Similar Executives
| Found 3 records | PRESIDENT Age | ||
| James Doherty | Acumen Pharmaceuticals | 56 | |
| Kelly Carranza | Acumen Pharmaceuticals | N/A | |
| Erin MD | Terns Pharmaceuticals | 53 | |
Management Performance
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.13 |
Viking Therapeutics Leadership Team
Elected by the shareholders, the Viking Therapeutics' board of directors comprises two types of representatives: Viking Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Viking. The board's role is to monitor Viking Therapeutics' management team and ensure that shareholders' interests are well served. Viking Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Viking Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| Michael Morneau, Vice Administration | ||
| Marianne Mancini, Chief Officer | ||
| Geoffrey Barker, Senior Development | ||
| Brian Lian, CEO and President and Director | ||
| Gregory Zante, Vice President - Finance and Operations |
Viking Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Viking Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.13 | ||||
| Current Valuation | 4.93 B | ||||
| Shares Outstanding | 111.44 M | ||||
| Shares Owned By Insiders | 5.96 % | ||||
| Shares Owned By Institutions | 75.48 % | ||||
| Number Of Shares Shorted | 13.28 M | ||||
| Price To Earning | (3.17) X | ||||
| Price To Book | 6.43 X | ||||
| EBITDA | (100.83 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Viking Stock Analysis
When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.